251 related articles for article (PubMed ID: 34053416)
1. Screening and identification of key genes in imatinib-resistant chronic myelogenous leukemia cells: a bioinformatics study.
Zhang H; Wang P; Song T; Bonnette UL; Zhang Z
Hematology; 2021 Dec; 26(1):408-414. PubMed ID: 34053416
[TBL] [Abstract][Full Text] [Related]
2. Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Study.
Hekmatshoar Y; Rahbar Saadat Y; Ozkan T; Bozkurt S; Karadag Gurel A
Nucleosides Nucleotides Nucleic Acids; 2024; 43(7):664-684. PubMed ID: 38117080
[TBL] [Abstract][Full Text] [Related]
3. Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic myelogenous leukemia.
He X; Deng Y; Yue W
Mol Med Rep; 2017 Jul; 16(1):523-532. PubMed ID: 28560425
[TBL] [Abstract][Full Text] [Related]
4. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells.
Yang Y; Zhong F; Jiang J; Li M; Yao F; Liu J; Cheng Y; Xu S; Chen S; Zhang H; Xu Y; Huang B
Hematology; 2023 Dec; 28(1):2244856. PubMed ID: 37594290
[TBL] [Abstract][Full Text] [Related]
6. Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments.
Zhao YH; Zhang XF; Zhao YQ; Bai F; Qin F; Sun J; Dong Y
J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):621-627. PubMed ID: 28786057
[TBL] [Abstract][Full Text] [Related]
7. MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate.
Martins JRB; Moraes LN; Cury SS; Capannacci J; Carvalho RF; Nogueira CR; Hokama NK; Hokama POM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638557
[TBL] [Abstract][Full Text] [Related]
8. Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib.
Avilés-Vázquez S; Chávez-González A; Hidalgo-Miranda A; Moreno-Lorenzana D; Arriaga-Pizano L; Sandoval-Esquivel MÁ; Ayala-Sánchez M; Aguilar R; Alfaro-Ruiz L; Mayani H
Cancer Med; 2017 Dec; 6(12):2942-2956. PubMed ID: 29030909
[TBL] [Abstract][Full Text] [Related]
9. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
10. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Wong SM; Liu FH; Lee YL; Huang HM
PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
[TBL] [Abstract][Full Text] [Related]
11. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
12. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
13. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
[TBL] [Abstract][Full Text] [Related]
14. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
15. p19
Kuang Y; Han X; Cao P; Xiong D; Peng Y; Liu Z; Xu Z; Liang L; Roy M; Liu J; Nie L; Zhang J
Blood Cells Mol Dis; 2020 Nov; 85():102477. PubMed ID: 32711219
[TBL] [Abstract][Full Text] [Related]
16. Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Karabay AZ; Koc A; Ozkan T; Hekmatshoar Y; Altinok Gunes B; Sunguroglu A; Buyukbingol Z; Atalay A; Aktan F
Hematology; 2018 Dec; 23(10):765-770. PubMed ID: 29945498
[TBL] [Abstract][Full Text] [Related]
17. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
18. Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
Liao HC; Chou YJ; Lin CC; Liu SH; Oswita A; Huang YL; Wang YL; Syu JL; Sun CM; Leu CM; Lin CH; Fu SL
Biochem Pharmacol; 2019 May; 163():308-320. PubMed ID: 30822403
[TBL] [Abstract][Full Text] [Related]
19. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
20. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
